Biofrontera Inc. BFRI 深 滬
已收盤 12-12 16:00:00 美东时间
0.8123
-0.001
-0.07%
華盛通- 最 高0.8251
- 今 開0.7923
- 成交量 5.34万股
- 最 低 0.7923
- 昨 收 0.8129
- 總市值 946.19万
- 52周最高 1.87
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.536
- 委 比 99.81%
- 總股本 1164.83万
- 歷史最高 292.60
- 量 比 1.27
- 振 幅 4.03%
- 歷史最低 0.536
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key
12-02 21:48
Biofrontera Q3 EPS $(0.62) Misses $(0.58) Estimate, Sales $6.988M Miss $7.000M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 36.73 percent increase over losses of $(0.98) per share from the
11-13 05:43
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Biofrontera Earnings Preview
Biofrontera (NASDAQ:BFRI) is gearing up to announce its quarterly earnings on W...
11-12 03:03
Biofrontera Regains Nasdaq Compliance in November 2025
Biofrontera ( ($BFRI) ) has provided an update. Biofrontera Inc. has announced ...
11-11 06:19
Biofrontera Completes Sale of Xepi US License
The latest announcement is out from Biofrontera ( ($BFRI) ). On November 6, 202...
11-07 21:29
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
11-07 20:52
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
Biofrontera Inc. has sold its U.S. rights to Xepi® (ozenoxacin) Cream, 1%, to Pelthos Therapeutics Inc., receiving $3 million upfront, $1 million upon commercial availability, and up to $6 million in milestones tied to sales targets. Proceeds will strengthen Biofrontera’s cash position and support growth of its photodynamic therapy platform and Ameluz® expansion. The transaction enables the company to focus on PDT development and profitability. X...
11-07 13:00
Biofrontera Finalizes U.S. Rights Acquisition Deal
Biofrontera ( ($BFRI) ) has shared an update. On October 20, 2025, Biofrontera ...
10-25 05:48
Biofrontera Completes Restructuring and Asset Purchase
Biofrontera ( ($BFRI) ) has issued an announcement. On October 23, 2025, Biofro...
10-23 21:21
